公开(公告)号：US12251365B2

公开(公告)日：2025-03-18

申请号：US16684874

申请日：2019-11-15

Applicant: AbbVie Inc.

Inventor： Ehab Moussa ,  Matthew Rosebraugh ,  Feroz Jameel ,  Nancy Sever ,  Maurizio F. Facheris ,  Weining Z Robieson ,  Charles S. Locke ,  Sven Stodtmann

IPC: A61P25/16 ,  A61K9/00 ,  A61K31/198 ,  A61K31/661

Abstract: The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.

公开(公告)号：US20160375017A1

公开(公告)日：2016-12-29

申请号：US15212997

申请日：2016-07-18

Applicant: AbbVie Inc.

Inventor： Katharina Asmus ,  Yi Gao ,  Colleen Garrett ,  Harald Hach ,  Adivaraha Jayasankar ,  Kyeremateng Samuel ,  Ute Lander ,  Thomas Mueller ,  Marius Naris ,  Constanze Obermiller ,  Regina Reul ,  Katrin Schneider ,  Nancy Sever ,  Michael Simon ,  Benedikt Steitz ,  Ping Tong ,  Ulrich Westedt ,  Donghua Zhu

IPC: A61K31/498 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K9/10

CPC classification number: A61K31/498 ,  A61K9/146 ,  A61K9/2027 ,  A61K9/209 ,  A61K31/454 ,  A61K31/4985 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract translation: 本发明的特征在于包含化合物1和化合物2的固体药物组合物。在一个实施方案中，固体药物组合物包括（1）包含100mg化合物1的第一层以及药学上可接受的亲水性聚合物和药学上可接受的表面活性剂， 所有这些都配制成无定形固体分散体; 和（2）包含40mg化合物2的第二层，以及药学上可接受的亲水性聚合物和药学上可接受的表面活性剂，所有这些都被配制成无定形固体分散体。

公开(公告)号：US20200155578A1

公开(公告)日：2020-05-21

申请号：US16684874

申请日：2019-11-15

Applicant: AbbVie Inc.

Inventor： Ehab Moussa ,  Matthew Rosebraugh ,  Feroz Jameel ,  Nancy Sever ,  Maurizio F. Facheris ,  Weining Z. Robieson ,  Charles S. Locke ,  Sven Stodtmann

IPC: A61K31/661 ,  A61K9/00 ,  A61P25/16

Abstract: The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.